Paris, April 26^th, 2023

Visiomed Group (FR0013481835 – ALVMG), a group specializing in innovative healthcare technologies and services, has filed its Annual Financial Report for the year ended December 31^st, 2022 with Euronext and made it available to the public (French version only).

As announced on January 26^th[1], Visiomed Group's financial performance improved strongly in 2022, with record revenue growth of 101% and normalized EBITDA of over €2 million excluding discontinued operations[2]. Financial net debt at year-end amounted €3.3 million.

All documents comprising the 2022 Annual Financial Report were approved by the Board of Directors on April 24^th, 2023 and may be found on the Group website: www.visiomed-group.com/en/financial-reports/.

About VISIOMED GROUP

Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.

The Group now has two subsidiaries and holdings:

• Smart Salem, the first digital medical analysis center accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates, 100% owned by Visiomed Group.

The Smart Salem offer is based on know-how in medical analysis, radiology and data analysis and processing to detect nearly 35 diseases in 7 minutes in a patient (in particular HIV, hepatitis and tuberculosis) by offering reliable results, readability and exceptional patient experience enabled by advanced artificial intelligence and virtual reality technologies.

Smart Salem's “Medical Fitness Assessment” offer resulting from this know-how thus makes it possible to obtain a residence or work visa in the space of 30 minutes compared to 10 to 15 days in historical health centers.

Smart Salem is a technological platform offering many growth opportunities, as shown by the opening of the second center in Dubai in September 2022 and the authorization received for the opening of a third center, planned to open in the first quarter of 2023.

• Bewellthy, created in 2022, a leading player in connected health and teleconsultation solutions and is 49.88% owned by Visiomed Group.

Bewellthy offers an enriched technological universe combining medical devices, software and "health and well-being concierge" services to meet all the needs and use cases of telehealth.

Bewellthy's flagship product, VisioCheck, is the 1^st telemedicine station weighing less than 300g for healthcare professionals, available as a case, station or modular healthcare space.

Bewellthy is now deploying its solutions and services in France and abroad, particularly in Italy and the USA.

Based in Paris, VISIOMED GROUP is listed on Euronext Growth (ALVMG). More information on www.visiomed-group.com.

CONTACTS

© Visiomed Group SA 2023. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.

[1] Record year 2022 marked by exceptional growth (99%), positive normalized EBITDA and strategic decisions opening up great prospects for 2023

[2] The differences versus the January 26^th press release (99% growth and €2.2 million normalized EBITDA excluding discontinued operations) are due to closing account entries and adjustments made following the statutory auditors' review.